ClinicalTrials.gg
CompletedNCT06566989Updated Oct 23, 2024

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

A Phase 1 interventional study of [¹⁴C]Opevesostat and Prednisone in Metastatic Prostate Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.

Enrollment
19th of 22
8 · median 93
Started
2024
with 2 others
Phase 1
6 of 22
none open now
Registered
20th of 22
by date

Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 19th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 20th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics (PK), metabolic profile, and safety and tolerability.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a healthy male according to the assessment of the investigator
  • Has a of 18.0 to 32.0 kg/m2
  • Has regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • Has the presence or history of allergy requiring treatment
  • Has a history of adrenal insufficiency
  • Has veins not suitable for multiple venipunctures/cannulation
  • Has previously taken part in more than 3 radiolabeled drug studies in the last 12 months
  • Has donated blood or plasma within the previous 3 months or lost greater than 400 mL of blood
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [¹⁴C]Opevesostat

    On Day 1, participants receive a single dose of \[¹⁴C\]opevesostat as an oral solution. Participants then receive single doses of 5.0 mg prednisone and 0.05 mg fludrocortisone tablets 4 hours later as hormone replacement therapy.

    Drug: [¹⁴C]Opevesostat · Drug: Prednisone · Drug: Fludrocortisone

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative amount of total radioactivity excreted in urine (CumAeu) after administration of single-dose [¹⁴C]Opevesostat

    Urine samples will be collected at pre-specified timepoints and used to determine CumAeu.

    Time frame: Predose and at designated time points (up to 8 days)

  2. Cumulative amount of total radioactivity excreted in feces (CumAef) after administration of single-dose [¹⁴C]Opevesostat

    Fecal samples will be collected at pre-specified timepoints and used to determine CumAef.

    Time frame: Predose and at designated time points (up to 8 days)

  3. Cumulative percentage of total radioactivity excreted in urine (Cumfeu) after administration of single-dose [¹⁴C]Opevesostat

    Urine samples will be collected at pre-specified timepoints and used to determine CumFeu.

    Time frame: Predose and at designated time points (up to 8 days)

  4. Cumulative percentage of total radioactivity excreted in feces (Cumfef) after administration of single-dose [¹⁴C]Opevesostat

    Fecal samples will be collected at pre-specified timepoints and used to determine Cumfef.

    Time frame: Predose and at designated time points (up to 8 days)

  5. Plasma Opevesostat Pharmacokinetics: Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)

    Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-t of opevesostat.

    Time frame: Predose and at designated time points (up to 8 days)

  6. Plasma Opevesostat Pharmacokinetics: Area under the curve from time 0 to extrapolated infinity (AUC0-inf)

    Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-inf of opevesostat.

    Time frame: Predose and at designated time points (up to 8 days)

  7. Plasma Opevesostat Pharmacokinetics: Maximum observed concentration (Cmax)

    Plasma samples will be collected at pre-specified timepoints and used to determine Cmax of opevesostat.

    Time frame: Predose and at designated time points (up to 8 days)

  8. Plasma Opevesostat Pharmacokinetics: Time of maximum observed concentration (Tmax)

    Plasma samples will be collected at pre-specified timepoints and used to determine Tmax of opevesostat.

    Time frame: Predose and at designated time points (up to 8 days)

  9. Plasma Opevesostat Pharmacokinetics: Terminal elimination half-life (t1/2)

    Plasma samples will be collected at pre-specified timepoints and used to determine t1/2 of opevesostat.

    Time frame: Predose and at designated time points (up to 8 days)

  10. Plasma Total Radioactivity Pharmacokinetics: Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)

    Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-t of total radioactivity.

    Time frame: Predose and at designated time points (up to 8 days)

  11. Plasma Total Radioactivity Pharmacokinetics: Area under the curve from time 0 to extrapolated infinity (AUC0-inf)

    Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-inf of total radioactivity.

    Time frame: Predose and at designated time points (up to 8 days)

  12. Plasma Total Radioactivity Pharmacokinetics: Maximum observed concentration (Cmax)

    Plasma samples will be collected at pre-specified timepoints and used to determine Cmax of total radioactivity.

    Time frame: Predose and at designated time points (up to 8 days)

  13. Plasma Total Radioactivity Pharmacokinetics: Time of maximum observed concentration (Tmax)

    Plasma samples will be collected at pre-specified timepoints and used to determine Tmax of total radioactivity.

    Time frame: Predose and at designated time points (up to 8 days)

  14. Plasma Total Radioactivity Pharmacokinetics: Terminal elimination half-life (t1/2)

    Plasma samples will be collected at pre-specified timepoints and used to determine t1/2 of total radioactivity.

    Time frame: Predose and at designated time points (up to 8 days)

  15. Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of Radioactivity

    Plasma samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: Predose and at designated time points (up to 8 days)

  16. Total Number of Metabolites in Urine that Represent at least 10% of the Dose of Radioactivity

    Urine samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: Predose and at designated time points (up to 8 days)

  17. Total Number of Metabolites in Feces that Represent at least 10% of the Dose of Radioactivity

    Fecal samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.

    Time frame: Predose and at designated time points (up to 8 days)

Secondary outcomes

  1. Number of Participants with One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who experienced an AE will be reported.

    Time frame: Up to approximately 8 days

  2. Number of Participants who Discontinue from the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue from the study due to an AE will be reported.

    Time frame: Up to approximately 8 days

07

Study locations

1 site
  • Quotient Sciences ( Site 0001)
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2024, 0 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 0 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 22, 2024
StartActual
Sep 19, 2024
Primary completionActual
Oct 17, 2024
CompletionActual
Oct 17, 2024
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06566989
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Sep 19, 2024
Primary completion
Oct 17, 2024
Completion
Oct 17, 2024
Last update
Oct 23, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opevesostat

Start the discussion